Mettler Toledo vs Boston Scientific
Side-by-side comparison of AI visibility scores, market position, and capabilities
Columbus OH precision instruments (NYSE: MTD) Q4 2024 revenue $1.045B (+12%), adjusted EPS $12.41 (+32%); global market leader lab balances and food inspection, pharma/biopharma lab destocking recovery competing with Sartorius.
About
Mettler-Toledo International Inc. is a Columbus, Ohio-based precision instruments and services company — publicly traded on the New York Stock Exchange (NYSE: MTD) as an S&P 500 Health Care component — manufacturing and marketing the world's most comprehensive range of weighing instruments and precision analytical measurement devices for laboratory, industrial, and food retail applications through approximately 18,000 employees in 40 countries. Mettler-Toledo's product portfolio spans laboratory balances and analytical instruments (used in pharmaceutical R&D and quality control), industrial scales and process analytics (used in chemical, food, and beverage manufacturing), pharmaceutical inspection systems (tablet and capsule inspection lines), food inspection equipment (X-ray and metal detection systems, checkweighers), and retail weighing solutions (supermarket scales). In Q4 2024, Mettler-Toledo reported revenue of $1.045 billion (+12% year-over-year) and adjusted EPS of $12.41 (+32% over the prior-year $9.40) — demonstrating the company's operational leverage as volume returned following the laboratory instruments market's destocking correction. CEO Patrick Kaltenbach has led Mettler-Toledo since 2020, maintaining the company's premium pricing strategy and capital return program (no dividend; all free cash flow directed to share repurchases that have reduced the share count by approximately 50% over the past decade). Mettler-Toledo operates as a category leader in precision weighing with 30%+ global market share and consistently achieves operating margins of 28-30%.
Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.
About
Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.